{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:58:13Z","timestamp":1761897493195,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To determine the utility of estimated glucose disposal rate (eGDR) as a candidate biomarker for thrombotic biomarkers in patients with type 1 diabetes (T1D).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We reanalysed baseline pretreatment data in a subset of patients with T1D from two previous RCTs, consisting of a panel of thrombotic markers, including fibrinogen, tissue factor (TF) activity, and plasminogen-activator inhibitor (PAI)-1, and TNF\u03b1, and clinical factors (age, T1D duration, HbA1c, insulin requirements, BMI, blood pressure, and eGDR). We employed univariate linear regression models to investigate associations between clinical parameters and eGDR with thrombotic biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-two patients were included [mean\u2009\u00b1\u2009SD age 31\u2009\u00b1\u20097\u00a0years, HbA1c of 58\u2009\u00b1\u20099\u00a0mmol\/mol (7.5\u2009\u00b1\u20090.8%), eGDR 7.73\u2009\u00b1\u20092.61]. eGDR negatively associated with fibrinogen (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), PAI-1 concentrations (<jats:italic>P<\/jats:italic>\u2009=\u20090.005), and TF activity (<jats:italic>P<\/jats:italic>\u2009=\u20090.020), but not TNF\u03b1 levels (<jats:italic>P<\/jats:italic>\u2009=\u20090.881). We identified 2 clusters of patients displaying significantly different characteristics; 56% (<jats:italic>n<\/jats:italic>\u2009=\u200918) were categorised as \u2018higher-risk\u2019, eliciting significantly higher fibrinogen (+\u20091514\u2009\u00b1\u2009594\u00a0\u03bcg\/mL; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), TF activity (+\u200959.23\u2009\u00b1\u20099.42\u00a0pmol\/mL; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and PAI-1 (+\u20098.48\u2009\u00b1\u20091.58\u00a0pmol\/dL; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), HbA1c concentrations (+\u200914.20\u2009\u00b1\u20091.04\u00a0mmol\/mol; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), age (+\u20097\u2009\u00b1\u20093\u00a0years; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), duration of diabetes (15\u2009\u00b1\u20092\u00a0years; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), BMI (+\u20097.66\u2009\u00b1\u20092.61\u00a0kg\/m<jats:sup>2<\/jats:sup>; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and lower mean eGDR (\u2212\u20093.98\u2009\u00b1\u20091.07; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared to BMI and insulin requirements, classical surrogates of insulin resistance, eGDR is a suitable and superior thrombotic risk indicator in T1D.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN4081115; registered 27 June 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-021-01550-3","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T11:02:41Z","timestamp":1615978961000},"page":"2417-2426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Estimated glucose disposal rate as a candidate biomarker for thrombotic biomarkers in T1D: a pooled analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-3290","authenticated-orcid":false,"given":"L. L.","family":"O\u2019Mahoney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-4450","authenticated-orcid":false,"given":"N.","family":"Kietsiriroje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4943-6759","authenticated-orcid":false,"given":"S.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-4925","authenticated-orcid":false,"given":"D. J.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-3725","authenticated-orcid":false,"given":"R. A.","family":"Ajjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-5041","authenticated-orcid":false,"given":"M. D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"issue":"1","key":"1550_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/EJE-14-0911","volume":"173","author":"E Donga","year":"2015","unstructured":"Donga E, Dekkers OM, Corssmit E, Romijn JA (2015) Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol 173(1):101\u2013109","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1550_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2337\/db10-0328","volume":"60","author":"IE Schauer","year":"2011","unstructured":"Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, Rewers M (2011) Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 60(1):306\u2013314","journal-title":"Diabetes"},{"issue":"2","key":"1550_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2337\/diacare.24.2.284","volume":"24","author":"N Chaturvedi","year":"2001","unstructured":"Chaturvedi N, Sjoelie A-K, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 24(2):284\u2013289","journal-title":"Diabetes Care"},{"issue":"9","key":"1550_CR4","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.2337\/db08-0332","volume":"57","author":"V-P M\u00e4kinen","year":"2008","unstructured":"M\u00e4kinen V-P, Forsblom C, Thorn LM, Wad\u00e9n J, Gordin D, Heikkil\u00e4 O, Hietala K, Kyll\u00f6nen L, Kyt\u00f6 J, Roseng\u00e5rd-B\u00e4rlund M (2008) Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 57(9):2480\u20132487","journal-title":"Diabetes"},{"issue":"39","key":"1550_CR5","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"ATF Members","year":"2013","unstructured":"Members ATF, Ryd\u00e9n L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H-P (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035\u20133087","journal-title":"Eur Heart J"},{"issue":"1","key":"1550_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","volume":"16","author":"K Kearney","year":"2017","unstructured":"Kearney K, Tomlinson D, Smith K, Ajjan R (2017) Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 16(1):34","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1550_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2796.2007.01824.x","volume":"262","author":"P Grant","year":"2007","unstructured":"Grant P (2007) Diabetes mellitus as a prothrombotic condition. J Intern Med 262(2):157\u2013172","journal-title":"J Intern Med"},{"key":"1550_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.thromres.2011.11.052","volume":"129","author":"N Vazzana","year":"2012","unstructured":"Vazzana N, Ranalli P, Cuccurullo C (2012) Dav\u0131G mellitus and thrombosis. Thromb Res 129:371\u2013377","journal-title":"Thromb Res"},{"issue":"4","key":"1550_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1177\/1479164117698918","volume":"14","author":"MD Campbell","year":"2017","unstructured":"Campbell MD, Walker M, Ajjan RA, Birch KM, Gonzalez JT, West DJ (2017) An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: a randomised controlled trial. Diab Vasc Dis Res 14(4):336\u2013344","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"1550_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000319196","volume":"64","author":"A Ozkul","year":"2010","unstructured":"Ozkul A, Turgut ET, Akyol A, Yenisey C, Kadikoylu G, Tataroglu C, Kiylioglu N (2010) The relationship between insulin resistance and hypercoagulability in acute ischemic stroke. Eur Neurol 64(4):201\u2013206","journal-title":"Eur Neurol"},{"issue":"31","key":"1550_CR11","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","volume":"34","author":"F Paneni","year":"2013","unstructured":"Paneni F, Beckman JA, Creager MA, Cosentino F (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34(31):2436\u20132443","journal-title":"Eur Heart J"},{"issue":"4","key":"1550_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2337\/diabetes.49.4.626","volume":"49","author":"KV Williams","year":"2000","unstructured":"Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49(4):626\u2013632. https:\/\/doi.org\/10.2337\/diabetes.49.4.626","journal-title":"Diabetes"},{"issue":"8","key":"1550_CR13","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.2337\/dc12-1693","volume":"36","author":"EJ Epstein","year":"2013","unstructured":"Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP (2013) Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 36(8):2280\u20132285. https:\/\/doi.org\/10.2337\/dc12-1693","journal-title":"Diabetes Care"},{"issue":"3","key":"1550_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/dom.13110","volume":"20","author":"T Nystr\u00f6m","year":"2018","unstructured":"Nystr\u00f6m T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U (2018) Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab 20(3):556\u2013563","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1550_CR15","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1111\/dom.13848","volume":"21","author":"N Kietsiriroje","year":"2019","unstructured":"Kietsiriroje N, Pearson S, Campbell M, Ari\u00ebns RA, Ajjan RA (2019) Double diabetes: a distinct high-risk group? Diabetes Obes Metab 21(12):2609\u20132618","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1550_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/j.1523-1755.2002.00507.x","volume":"62","author":"TJ Orchard","year":"2002","unstructured":"Orchard TJ, Chang Y-F, Ferrell RE, Petro N, Ellis DE (2002) Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62(3):963\u2013970","journal-title":"Kidney Int"},{"issue":"2","key":"1550_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/meta.2002.30021","volume":"51","author":"JC Olson","year":"2002","unstructured":"Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ (2002) Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabol Clin Exp 51(2):248\u2013254","journal-title":"Metabol Clin Exp"},{"issue":"5","key":"1550_CR18","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2337\/diacare.26.5.1374","volume":"26","author":"TJ Orchard","year":"2003","unstructured":"Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Kinder LS, Ellis D, Becker DJ (2003) Insulin resistance\u2013related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diabetes Care 26(5):1374\u20131379","journal-title":"Diabetes Care"},{"issue":"5","key":"1550_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2337\/dc06-2053","volume":"30","author":"G Pambianco","year":"2007","unstructured":"Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30(5):1248\u20131254","journal-title":"Diabetes Care"},{"issue":"1","key":"1550_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12933-020-01094-5","volume":"19","author":"LL O'Mahoney","year":"2020","unstructured":"O\u2019Mahoney LL, Dunseath G, Churm R, Holmes M, Boesch C, Stavropoulos-Kalinoglou A, Ajjan RA, Birch KM, Orsi NM, Mappa G, Price OJ, Campbell MD (2020) Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial. Cardiovasc Diabetol 19(1):127\u2013127. https:\/\/doi.org\/10.1186\/s12933-020-01094-5","journal-title":"Cardiovasc Diabetol"},{"key":"1550_CR21","unstructured":"NICE (2019) Hypertension in adults: diagnosis and management"},{"key":"1550_CR22","unstructured":"NICE guideline [NG136]. https:\/\/www.nice.org.uk\/guidance\/ng136. Accessed 12\/05\/2020"},{"issue":"3","key":"1550_CR23","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/j.diabres.2012.02.004","volume":"96","author":"CM Girgis","year":"2012","unstructured":"Girgis CM, Scalley BD, Park KE (2012) Utility of the estimated glucose disposal rate as a marker of microvascular complications in young adults with type 1 diabetes. Diabetes Res Clin Pract 96(3):e70\u2013e72","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"1550_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0168-8227(99)00095-9","volume":"46","author":"WW Nazaimoon","year":"1999","unstructured":"Nazaimoon WW, Letchuman R, Noraini N, Ropilah A, Zainal M, Ismail I, Mohamad WW, Faridah I, Singaraveloo M, Sheriff I (1999) Systolic hypertension and duration of diabetes mellitus are important determinants of retinopathy and microalbuminuria in young diabetics. Diabetes Res Clin Pract 46(3):213\u2013221","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"1550_CR25","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1007\/BF03347077","volume":"34","author":"T Rodrigues","year":"2011","unstructured":"Rodrigues T, Canani L, Schvartzman P, Gross J (2011) Hypertension is the metabolic syndrome component most strongly associated with microvascular complications and coronary artery calcification in type 1 diabetes. J Endocrinol Invest 34(3):e58\u2013e63","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1550_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1464-5491.1991.tb01606.x","volume":"8","author":"K N\u00f8rgaard","year":"1991","unstructured":"N\u00f8rgaard K, Feldt-Rasmussen B, Deckert T (1991) Is hypertension a major independent risk factor for retinopathy in type 1 diabetes? Diabet Med 8(4):334\u2013337","journal-title":"Diabet Med"},{"issue":"13","key":"1550_CR27","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","volume":"39","author":"W Sumaya","year":"2018","unstructured":"Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA (2018) Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J 39(13):1078\u20131085","journal-title":"Eur Heart J"},{"key":"1550_CR28","doi-asserted-by":"crossref","unstructured":"King R, Ajjan R (2016) Hypoglycaemia, thrombosis and vascular events in diabetes. Taylor and Francis","DOI":"10.1080\/14779072.2016.1215916"},{"issue":"3","key":"1550_CR29","first-page":"340","volume":"28","author":"AAM Adly","year":"2014","unstructured":"Adly AAM, Elbarbary NS, Ismail EAR, Hassan SR (2014) Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness. JDC 28(3):340\u2013347","journal-title":"JDC"},{"key":"1550_CR30","doi-asserted-by":"publisher","first-page":"17714","DOI":"10.1038\/srep17714","volume":"6","author":"J Yarmolinsky","year":"2016","unstructured":"Yarmolinsky J, Barbieri NB, Weinmann T, Ziegelmann PK, Duncan BB, Schmidt MI (2016) Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies. Sci Rep 6:17714","journal-title":"Sci Rep"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01550-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01550-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01550-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T14:54:47Z","timestamp":1633877687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01550-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01550-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest or competing interests relevant to this article are reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The RCT received ethical approval from the UK National Health Service Health Research Authority (REC Reference 17\/NE\/0244).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants gave written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}